Given these findings, it is convenient to classify the dermatitis as acute or chronic, to indicate whether or not it is of a specific morphologic type and to indicate the cause or causes if ...

scaling and vesiculation in acute dermatitis, and fissuring, lichenification and hyperkeratosis in the chronic phase, are largely nonspecific signs. Acute ICD Acute; often single exposure to ...

Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

In a second case, a 57-year-old woman with a urostomy due to carcinoma of the bladder developed an acute dermatitis around the stoma. Patch testing resulted in positive reactions to nickel sulfate ...

Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in ...

Scratching your skin can feel satisfying, but learn how it impacts inflammation and bacterial infection defense.